Free Trial
NASDAQ:IMA

ImageneBio Q3 2024 Earnings Results & Report

ImageneBio logo
$4.18 -0.06 (-1.39%)
As of 09:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ImageneBio beat analyst earnings expectations in its Q3 2024 results, released November 7, 2024. The company reported EPS of -$2.28 versus the -$3.24 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2024
Report Date
Conference Call
7:00 AM ET

ImageneBio EPS Results

Actual EPS
-$2.28
Consensus EPS
-$3.24
Beat/Miss
Beat by +$0.96
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

ImageneBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

ImageneBio Q3 2024 Earnings FAQ

ImageneBio (NASDAQ:IMA) reported earnings of -$2.28 per share for Q3 2024, beating the consensus estimate of -$3.24. The report was announced on Thursday, November 7, 2024.

ImageneBio Earnings Headlines

Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.tc pixel
ImageneBio Corporate Event Calendar | NASDAQ:IMA
See More ImageneBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email.

About ImageneBio

ImageneBio (NASDAQ:IMA) is a biotechnology company focused on developing molecular diagnostic technologies for precision oncology. The company aims to generate actionable information about cancer biology from blood-based samples, supporting more informed treatment decisions and disease monitoring.

ImageneBio’s platform is designed to analyze tumor-derived molecular signals and may support applications such as cancer detection, treatment selection, and monitoring of treatment response or disease progression. Its work is intended to complement conventional tissue-based testing by providing less-invasive access to tumor information.

The company is headquartered in Israel and serves the global biopharmaceutical and clinical research markets. Publicly available information about its product portfolio, commercial reach, and leadership team remains limited.

View ImageneBio Profile